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Abstract
Considering the role of hemorheology in coronary circulation, we studied blood viscosity in patients with juvenile myocardial
infarction. We examined whole blood viscosity at high shear rate using the cone-on-plate viscosimeter Wells-Brookfield ½ LVT
and at low shear rate employing a viscometer Contraves LS30 in 120 patients (aged <46 years) with myocardial infarction, at the
initial stage and subsequently 3 and 12 months after. At the initial stage, patients had an increased whole blood viscosity in
comparison to normal controls. This hemorheological profile was not influenced by the cardiovascular risk factors, nor by the
extent of coronary lesions, even if some differences were evident between patients with ST-segment elevation myocardial
infarction (STEMI) and non-STEMI (NSTEMI). The blood viscosity pattern at the initial stage did not influence recurring ischemic
events or the onset of heart failure during an 18 months’ follow-up. The neutrophil to lymphocyte ratio did not affect the blood
viscosity pattern. We reevaluated 83 patients 3 months after and 70 patients 12 months after the acute coronary syndrome, and
we found that the hemorheological parameters were still altered in comparison to normal controls at both times. We observed
an impairment of the hemorheological pattern in young patients with myocardial infarction, partially influenced by the infarction
type (STEMI and NSTEMI) and persisting in the long term.
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Introduction
Blood viscosity influences the risk of cardiovascular events1
and plays a role in the pathophysiology of thrombosis2 and
atherothrombosis.3,4 Several studies have explored blood visc-
osity in acute myocardial infarction (AMI) and its influence on
some clinical and prognostic aspects. Some hemorheological
variables seemed to distinguish ST-segment elevation myocar-
dial infarction (STEMI) from patients with non-STEMI
(NSTEMI),5 but this finding was not confirmed by another
study.6 In patients with STEMI, a significant correlation
between the left ventricular ejection fraction (LVEF) and some
hemorheological parameters was observed.7 Some authors
described prolonged hemorheological impairment in AMI sur-
vivors not selected for age,8 and a similar behavior was
observed in the follow-up of patients with acute coronary syn-
dromes.9 All these literature data take on a specific relevance
considering the role of blood viscosity in the regulation of
myocardial microcirculation10 and coronary blood flow11 and
the interaction between blood viscosity and endothelium.12 An
impairment of blood rheology could be involved in the phe-
nomenon of secondary coronary slow flow: the slow progres-
sion of the contrast medium through the coronary tree in the
absence of demonstrated organic lesions.13-15 In a small group
of patients with slow coronary flow, an alteration in erythrocyte
aggregation was observed.16
The neutrophil to lymphocyte ratio (NLR) is considered as a
prognostic factor in AMI.17-21 It seems to reflect the systemic
inflammatory condition induced by AMI, and in fact, it is
positively correlated with high sensitivity-C reactive protein
(hs-CRP)in patients with AMI22,23 as well as in healthy
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patients.24 Previously, in small groups of patients with juvenile
myocardial infarction belonging to this survey, we examined,
as indicator of inflammation, elastase, a plasma marker of
polymorphonuclear (PMN) leukocyte activation, that was sig-
nificantly increased in comparison to normal controls, not only
at the initial stage but also at three25 and twelve26 months after
AMI. As it is known, elastase seems to reflect the inflammation
status that characterizes these patients. Until now, the possible
relation between NLR and the blood rheology profile in AMI
has not been investigated.
Acute myocardial infarction has a low incidence in young
adults, between 2% and 10% of all cases with AMI.27-31 Acute
myocardial infarction32-34 or acute coronary syndromes35,36 in
young patients show peculiar risk factors, clinical, angiographic,
and prognostic characteristics. In juvenile myocardial infarction,
the risk factor pattern is different from older people. Cigarette
smoking is the most common factor, followed by family history
of coronary artery disease (CAD). In younger people, hyperch-
olesterolemia is the third cardiovascular risk factor, while arter-
ial hypertension and diabetes mellitus are not frequent.
Regarding the clinical picture, young patients reach hospital
earlier than other patients, helping efficacy of revascularization
and complication treatment. In young people, often there is not
CAD or just 1 coronary vessel is affected by significant narrow-
ing; 3-vessel disease is infrequent. Consequently, the reperfusion
with percutaneous intervention is more frequent than coronary
artery bypass graft, and this has a favorable influence on prog-
nosis. In young people, AMI seems to have a lower incidence of
complications such as early and late heart failure, angina, rein-
farct, and atrioventricular block. Death during hospitalization
and after 6 months are both significantly reduced.
Since 2001, we have participated in the “Sicilian study on
juvenile myocardial infarction,” evaluating the hemorheological
profile in patients who had AMI at an age <46 years. The inves-
tigation was carried out at the initial stage and 3 and 12 months
after the AMI onset. In our previous reports,37,38 we described an
increase in whole blood viscosity (WBV), plasma and serum
viscosity, and a decrease in erythrocyte deformability.
In this conclusive study, we reexamined the data previously
obtained in young patients with AMI in the light of the
follow-up performed in most of them. Although the short-
term prognosis of AMI is favorably influenced by young age,34
the long-life expectancy of these patients makes the control of
their long-term risk profile particularly relevant.
Materials and Methods
The enrollment of patients with recent AMI aged <46 years
lasted from 2001 to 2007. In each patient, we examined the
main cardiovascular risk factors, including current smoking
habits, family history of CAD, hypercholesterolemia, arterial
hypertension, and diabetes mellitus. Family history consisted
in any first-grade relative with clinical manifestation of CAD
at age <55 years. Hypercholesterolemia was defined as a total
cholesterol level >220 mg/dL and/or the use of lipid-lowering
drugs. Arterial hypertension was defined as a systolic blood
pressure >140 mm Hg and/or a diastolic blood pressure
>90 mm Hg and/or the use of antihypertensive drugs. Dia-
betes mellitus was defined as a fasting blood glucose level
126 mg/dL and/or the use of hypoglycemic agents. Coron-
ary angiography was performed in all the patients, except
when consent was refused or when the hospital in which the
AMI was diagnosed was very far from the Cardiac Catheter-
ization Laboratory of our University Hospital.
In each patient, LVEF was evaluated by echocardiography.
On fasting venous blood, we evaluated the following hemor-
heological determinants:
 WBV at the shear rate of 450 s1, using the cone-on-
plate viscometer Wells-Brookfield ½ LVT (Middleboro,
Massachusetts);
 WBV at the shear rate of 0.51 s1 employing a visc-
ometer Contraves LS30 (proRheo GmbH, Althengstett,
Germany);
 Hematocrit (Ht) obtained using a micromethod
technique;
 WBV at 450 s1/Ht  100; and
 WBV at 0.51 s-1/Ht  100.
An automated blood cell count was carried out on the same
sample used for the hemorheological evaluation and employed
to calculate the NLR.
The same variables were measured in 83 patients with AMI
3 months after AMI and in 70 patients 12 months after AMI.
A clinical follow-up of the patients with AMI was con-
ducted to investigate about the onset of new ischemic events
or heart failure. We analyzed data obtained from 98 patients
followed up to 18 months after the initial AMI, including
some patients in whom the rheological evaluation at 3 and/or
12 months had not been performed.
The rheological study was also performed in a group of 50
control patients free of medical diseases as assessed by clinical
history, physical examination, electrocardiography, and routine
hematological and urine analysis. The ethical committee
approved the study, and each patient gave informed consent.
Statistical Analysis
Data were expressed as means (standard deviation [SD]) The
Student t test for unpaired data was used to compare normal
controls to patients with AMI. The differences in demographic
characteristics other than age were evaluated using the Fisher
exact test. The subgroups of patients with AMI with a different
number of risk factors or stenosed coronary vessels were com-
pared using the 1-way analysis of variance model, completed
by the Bonferroni posttest. At the initial stage, patients with
AMI were also divided into 2 subgroups according to different
criteria (see Results section), and every time the Student t test
for unpaired data was employed to compare the subgroups
between each other. The correlation between LVEF and
hemorheological parameters was examined using the linear
regression. The difference between the hemorheological
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parameters at the initial stage and those at 3 and 12 months,
respectively, was examined using the Student t test for unpaired
data.
Results
We enrolled 120 patients (109 men and 11 women) with recent
AMI. The demographic characteristics of control patients and
patients with AMI are shown in Table 1. Patients with AMI
were older than control patients (P < .001), although the age
range was similar. No difference was present in gender or body
weight distribution. The time interval between AMI onset and
the initial examination was 13 (7) days.
Left ventricular ejection fraction was 54.52 (7.31%) in
the whole group; in patients with STEMI (n ¼ 86), LVEF
was 53.88 (7.72%), and in patients with NSTEMI (n ¼ 34),
the LVEF was 56.14% (6.00%; not significantly different vs
STEMI).
Patients with AMI were subdivided into 3 groups, having 0
or 1, 2, and 3 or more risk factors, respectively. Thirty-nine
patients had 0 or 1 risk factor, 39 had 2 risk factors, and 42 had
3 or more of them. Coronary angiography was performed in
103 patients, subdivided into 3 groups according to the extent
of coronary lesions: 23 patients did not show any significant
coronary stenosis, 46 had a single-vessel disease (defined as a
stenosis >70% in 1 coronary artery), and 34 had a multivessel
disease, defined as a stenosis >70% in at least 2 coronary
vessels.
During the follow-up, 5 patients developed heart failure, 15
a new ischemic event (12 angina and 3 AMI), and 4 a new
ischemic event associated with heart failure.
At the initial stage, patients with AMI showed significantly
higher levels of rheological determinants in comparison to
control patients (P < .001), with the exception of Ht (Table 2).
Subdividing patients with AMI according to the number of
cardiovascular risk factors and to the number of involved cor-
onary vessels, no significant difference was noted in any of the
rheological variables.
At the initial stage, we subdivided patients with AMI
according to 3 criteria: STEMI or NSTEMI; with or without
ischemic events and/or heart failure at follow-up; and high or
low NLR.
We found a difference in WBV at 450 sec1 (P < .01) and in
WBV at 450 sec1/Ht ratio (P < .05) between patients with
STEMI and NSTEMI; both parameters were in fact higher in
STEMI in comparison to patients with NSTEMI (Table 3).
In the whole group, as well as in the 2 subgroups with
STEMI or NSTEMI, no correlation between each hemorheo-
logical variable and LVEF was observed.
We compared the rheological determinants at the initial
stage in patients with AMI who subsequently developed recur-
rent ischemic event or heart failure (n¼ 24) to those of patients
who were free from such complications up to 18 months
(n¼ 74). From this analysis (Table 4), no significant difference
emerged between the 2 groups.
Table 1. Demographic Characteristics in Control Patients and
Patients With AMI.
Demographic Characteristics
Control
Patients
Patients With
AMI
Age, means (SD), years 35.1 (7.8) 39.4 (5.8)a
Age range, years 19-46 19-45
Male, n (%) 40 (80%) 109 (91%)
Normal weight (BMI < 25 kg/m2), n (%) 14 (28%) 30 (25%)
Overweight (BMI 25-29.9 kg/m2), n (%) 20 (40%) 54 (45%)
Obesity (BMI > 30 kg/m2), n (%) 16 (32%) 36 (30%)
Abbreviations: AMI, acute myocardial infarction; BMI, body mass index.
aP < .001 versus control patients (Student t test for unpaired data).
Table 2. Means (SD) of the Hemorheological Determinants in 50
Control Patients and in 120 Patients With AMI at the Initial Stage.
Demographic
Characteristics
Control
Patients AMI at the Initial Stage
WBV 450 sec1, mPas 3.534 (0.376) 4.337 (0.436)a
WBV 0.51 sec1, mPas 23.51 (10.53) 30.74 (7.65)a
Ht (%) 45.20 (2.84) 44.34 (3.70)
WBV 450/Ht  100 7.932 (0.803) 9.872 (0.891)a
WBV 0.51/Ht  100 51.63 (21.89) 69.24 (13.22)a
Abbreviations: AMI, acute myocardial infarction; Ht, hematocrit; SD, standard
deviation; WBV, whole blood viscosity.
aP < .001 versus control patients (Student t test for unpaired data).
Table 3. Means (SD) of the Hemorheological Determinants at the
Initial Stage in Patients With AMI With or Without ST-Segment
Elevation.
Demographic Characteristics
Patients With
STEMI
Patients With
NSTEMI
WBV 450 sec1, mPas 4.420 (0.386) 4.140 (0.500a)
WBV 0.51 sec1, mPas 31.09 (6.76) 29.97 (10.18)
Ht (%) 44.48 (3.42) 44.40 (4.43)
WBV 450/Ht  100 9.997 (0.794) 9.529 (1.071b)
WBV 0.51/Ht  100 69.95 (12.18) 66.85 (16.26)
Abbreviations: AMI, acute myocardial infarction; Ht, hematocrit; STEMI,
ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment
elevation myocardial infarction; WBV, whole blood viscosity.
aP < 0.01 versus patients with STEMI (Student t test for unpaired data).
bP < 0.05 versus patients with STEMI (Student t test for unpaired data).
Table 4. Means (SD) of the Hemorheological Determinants at the
Initial Stage in Patients With AMI With or Without Cardiovascular
Events During Follow-Up.
Demographic
Characteristics
Patients With
AMI With Events
Patients With
AMI Without Events
WBV 450 sec1, mPas 4.266 (0.396) 4.351 (0.453)
WBV 0.51 sec1, mPas 31.41 (10.75) 30.16 (7.25)
Ht (%) 44.58 (4.25) 44.35 (3.64)
WBV 450/Ht  100 9.755 (0.836) 9.877 (0.941)
WBV 0.51/Ht  100 70.04 (17.38) 67.96 (12.61)
Abbreviations: AMI, acute myocardial infarction; Ht, hematocrit; WBV, whole
blood viscosity.
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We further subdivided the whole group of patients with
AMI according to the median value of NLR, and there were
no differences between the 2 subgroups (Table 5).
When we reexamined the patients with AMI 3 and 12
months after the acute event (Table 6), we observed that at
both times the rheological determinants showed higher values
in comparison to those found in normal controls (P < .001 for
all the parameters at both times, with the exception of WBV at
0.51 sec-1 at 12 months, for which P < .01). No significant
difference was present between rheological variables at 3 and
12 months.
Discussion
Our data show that in young patients with AMI, a hypervisc-
osity syndrome is present as widely demonstrated in patients
with AMI not selected for age. These data confirm our previ-
ous results37,38 but differ from what was found by other
authors in a group of patients with similar age who had expe-
rienced an AMI 3 to 24 months earlier and whose plasma and
blood viscosity values were not different from controls.39 This
latter data may be explained considering that the young
patients with AMI were examined within a wider time interval
from the acute event.
We observed an increased blood viscosity at high shear rate
in patients with STEMI compared to patients with NSTEMI. In
another study, ST-segment elevation did not influence the
rheological profile of patients with AMI,6 while other authors
observed an increase in blood viscosity at low shear rate in
STEMI compared to NSTEMI and unstable angina.5
In our patients with AMI, the rheological pattern was not
dependent on the number of cardiovascular risk factors or on
the extent of coronary lesions as reported previously.37,38
We did not observe any significant correlation between
LVEF and each rheological variable in the whole group of
patients with AMI or in STEMI and NSTEMI subgroups; in
older patients with STEMI, a correlation between LVEF and
blood viscosity was observed,7 but in another study, only
plasma viscosity was related to LVEF.8
Neither the subdivision based on cardiac complications dur-
ing the 18 months’ follow-up nor that based on NLR showed a
difference in blood viscosity pattern. Differently, plasma visc-
osity in the same group of patients with AMI was significantly
higher in patients who subsequently developed new ischemic
events and/or heart failure and in those with high NLR.40
A main point of this study was the persistence of the rheo-
logical abnormalities 3 and 12 months after AMI, a behavior
already described by us in smaller groups of patients.37,38
The hyperviscosity syndrome early detected after AMI has
been commonly considered as part of an acute-phase reaction,
likely to regress in a few weeks. In patients not selected for age,
such behavior was in fact described in some studies,41-45 while
other authors observed a persistent rheological alteration.8,9,46,47
In our study, patients with AMI, after hospital discharge,
received a prescription of drugs according to current recom-
mendations (antiplatelet agent in 96.7%, statin in 75.3%, and a
b-blocker in 64.4%) and were provided with counseling about
lifestyle. As assessed during the follow-up, most of the patients
gave up smoking and started to exercise regularly; those
affected by arterial hypertension and diabetes mellitus
achieved a better control of their diseases. Despite a satisfac-
tory compliance with treatment, the hemorheological alteration
persisted, substantially unchanged until 12 months after AMI.
A similar long-term persistence of alterations after AMI
was also evident when we examined aspects of PMN leuko-
cytes, such as membrane fluidity and cytosolic Caþþ concen-
tration at baseline and after in vitro activation,48 plasma
markers of PMN and platelet activation,49 and some para-
meters of the oxidative status.50
These abnormalities could be partially caused by a proin-
flammatory genetic pattern and could favor the onset of AMI at
a relatively young age. A high prevalence of some pro-
inflammatory gene polymorphisms was actually observed in
the Sicilian study on juvenile AMI.51
Young patients with AMI could be a subset of patients with
CAD whose proinflammatory genetic pattern, interacting with
acquired factors such as smoking, precipitates acute myocar-
dial ischemia.
The hemorheological abnormality that persists 12 months
after the AMI onset needs a particular attention, especially
considering the long-life expectancy of young patients with
AMI. The follow-up of young patients with AMI performed
Table 5. Means (SD) of the Hemorheological Determinants at the
Initial Stage in Patients With AMI Having Low or High Neutrophil/
Lymphocyte Ratio.
Demographic
Characteristics
Patients With AMI
With Low NLR
Patients With AMI
With High NLR
WBV 450 sec1, mPas 4.330 (0.405) 4.345 (0.468)
WBV 0.51 sec1, mPas 30.18 (6.19) 31.22 (8.73)
Ht (%) 44.82 (3.35) 43.87 (3.99)
WBV 450/Ht  100 9.735 (0.969) 10.01 (0.787)
WBV 0.51/Ht  100 67.55 (10.95) 70.70 (14.86)
Abbreviations: AMI, acute myocardial infarction; Ht, hematocrit; NLR, neutro-
phil lymphocyte ratio; WBV, whole blood viscosity.
Table 6. Means (SD) of the Hemorheological Determinants in
Control Patients and Patients With AMI After 3 and 12 Months.
Demographic
Characteristics
Control
Patients
Patients With
AMI After
3 Months
Patients With
AMI After
12 Months
WBV 450 sec1, mPas 3.534 (0.376) 4.263 (0.440)a 4.241 (0.342)a
WBV 0.51 sec1, mPas 23.51 (10.53) 30.62 (6.52)a 29.13 (6.42)b
Ht (%) 45.20 (2.84) 44.92 (3.80) 45.04 (3.66)
WBV 450/Ht  100 7.932 (0.803) 9.595 (0.819)a 9.563 (0.458)a
WBV 0.51/Ht  100 51.63 (21.89) 67.88 (11.64)a 64.86 (10.79)a
Abbreviations: AMI, acute myocardial infarction; Ht, hematocrit; WBV, whole
blood viscosity.
aP < .001 versus control patients (Student t test for unpaired data).
bP < .01 versus control patients (Student t test for unpaired data).
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by us is still short and does not allow us to hypothesize a
prognostic role for hemorheological abnormalities, although
in our patients plasma viscosity was higher in those who sub-
sequently experienced adverse cardiac events.40
A limitation of this further analysis of our survey of young
patients with AMI is the lack of information about the hemor-
heological pattern later than 12 months after the acute event so
that the relationship with the long-term clinical outcome
remains questionable. However, considering the prognostic
role of the rheological profile in cardiovascular morbidity and
mortality,52 the assessment of blood viscosity in patients with
AMI at young age might deserve particular attention.
Conclusions
In conclusion, we observed an impairment of the blood rheo-
logical profile in patients who had AMI at a young age, par-
tially influenced by the type of AMI (STEMI or NSTEMI). The
persistence of the alteration after 3 and 12 months suggests a
genetic mechanism and could have a prognostic relevance.
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